Medica l Image Ana lysis & Ar t i f icia l Intel l igence Symposium 2022 Nr. 7: Dr. Olgica Zaric, PhD, MSc: Tissue Sodium Concentration Quantification at 7.0-T MRI as an Early Marker for Chemotherapy Response in Breast Cancer: A Feasibility Stud Curriculum Vitae: Dr. Olga Zaric has been dedicated to the development and implementation of advanced magnetic resonance imaging (MRI) techniques, such as diffusion-weighted imaging (DWI), sodium (23Na), and chemical exchange saturation transfer (CEST) imaging in breast tumor characterization and treatment efficacy monitoring. Her future research will be focused on retrospective analyses of the radiomics derived from patient data who have undergone multiparametric MRI scans and on prospective studies, such as sodium fingerprinting imaging and employment of deep learning techniques to develop predictors for breast lesions diagnosis and classification and early response to immune checkpoint inhibitors (ICI) treatments. The studies will be performed in a collaboration of DPU and High Field MR Centre, MUV as part of joint projects whose preparation is currently in progress. Abstract: Tissue Sodium Concentration Quantification at 7.0-T MRI as an Early Marker for Chemotherapy Response in Breast Cancer: A Feasibility Study In this study, we investigated the feasibility of the imaging protocol tissue sodium concentration (TSC) quantification at 7.0-T MRI as an early marker for chemotherapy response follow-up in women with breast cancer. We aimed to explore whether the early changes of TSC can better predict a pathologic complete response (pCR) in women with locally advanced breast cancer than can changes in tumor size. When comparing our quantitative results with histologic findings, we found that the area under the receiver operating characteristic curve for tissue sodium concentration (TSC) reduction can better differentiate between participants with and without a pCR after the first chemotherapy cycle than can two-dimensional tumor size reduction. We, therefore, conclude that TSC is a promising imaging marker for the identification of patients with a poor prognosis and advanced progression of breast cancer, and it could play a crucial role in improving personalized breast cancer treatment in the future.